alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Fusions'],"[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]",['Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.'],LEVEL_1,LEVEL_Fda2,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}",[],"['16960151', '12676775', '12181402', '14504092', '18950453', '24687085', '22897847', '26355392', '1516603']",[],"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Numerous small clinical trials and case reports have demonstrated the striking efficacy of imatinib for the treatment of myeloproliferative neoplasms with PDGFRB translocations/fusions (PMID: 12181402, 16960151, 18950453, 22897847, 14504092, 26355392), the largest of which (n=26) showed an overall response rate of 96% and ten-year overall survival of 90% in such patients (PMID: 24687085). In total, case studies have indicated that about 45% of patients have complete responses to imatinib and 39% have major responses (PMID: 1516603, 12676775). In a long-term study of twelve patients with chronic myeloproliferative disorders harboring PDGFRB fusions who were treated with imatinib, all patients showed a rapid response to treatment as measured by complete molecular and cytogenetic remission, and the median duration of cytogenetic responses was 47 months with only two patients progressing to relapse and death (PMID: 16960151)."
['Fusions'],"[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]",['Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.'],LEVEL_1,LEVEL_Fda2,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}",[],"['16960151', '12676775', '12181402', '14504092', '18950453', '24687085', '22897847', '26355392', '1516603']",[],"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Numerous small clinical trials and case reports have demonstrated the striking efficacy of imatinib for the treatment of myeloproliferative neoplasms with PDGFRB translocations/fusions (PMID: 12181402, 16960151, 18950453, 22897847, 14504092, 26355392), the largest of which (n=26) showed an overall response rate of 96% and ten-year overall survival of 90% in such patients (PMID: 24687085). In total, case studies have indicated that about 45% of patients have complete responses to imatinib and 39% have major responses (PMID: 1516603, 12676775). In a long-term study of twelve patients with chronic myeloproliferative disorders harboring PDGFRB fusions who were treated with imatinib, all patients showed a rapid response to treatment as measured by complete molecular and cytogenetic remission, and the median duration of cytogenetic responses was 47 months with only two patients progressing to relapse and death (PMID: 16960151)."
['Fusions'],"[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]",['Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.'],LEVEL_1,LEVEL_Fda2,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}",[],"['16960151', '12676775', '12181402', '14504092', '18950453', '24687085', '22897847', '26355392', '1516603']",[],"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Numerous small clinical trials and case reports have demonstrated the striking efficacy of imatinib for the treatment of myeloproliferative neoplasms with PDGFRB translocations/fusions (PMID: 12181402, 16960151, 18950453, 22897847, 14504092, 26355392), the largest of which (n=26) showed an overall response rate of 96% and ten-year overall survival of 90% in such patients (PMID: 24687085). In total, case studies have indicated that about 45% of patients have complete responses to imatinib and 39% have major responses (PMID: 1516603, 12676775). In a long-term study of twelve patients with chronic myeloproliferative disorders harboring PDGFRB fusions who were treated with imatinib, all patients showed a rapid response to treatment as measured by complete molecular and cytogenetic remission, and the median duration of cytogenetic responses was 47 months with only two patients progressing to relapse and death (PMID: 16960151)."
['Fusions'],"[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]",['Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.'],LEVEL_1,LEVEL_Fda2,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}",[],"['16960151', '12676775', '12181402', '14504092', '18950453', '24687085', '22897847', '26355392', '1516603']",[],"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Numerous small clinical trials and case reports have demonstrated the striking efficacy of imatinib for the treatment of myeloproliferative neoplasms with PDGFRB translocations/fusions (PMID: 12181402, 16960151, 18950453, 22897847, 14504092, 26355392), the largest of which (n=26) showed an overall response rate of 96% and ten-year overall survival of 90% in such patients (PMID: 24687085). In total, case studies have indicated that about 45% of patients have complete responses to imatinib and 39% have major responses (PMID: 1516603, 12676775). In a long-term study of twelve patients with chronic myeloproliferative disorders harboring PDGFRB fusions who were treated with imatinib, all patients showed a rapid response to treatment as measured by complete molecular and cytogenetic remission, and the median duration of cytogenetic responses was 47 months with only two patients progressing to relapse and death (PMID: 16960151)."
['Fusions'],"[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]",['Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.'],LEVEL_1,LEVEL_Fda2,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}",[],"['16960151', '12676775', '12181402', '14504092', '18950453', '24687085', '22897847', '26355392', '1516603']",[],"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Numerous small clinical trials and case reports have demonstrated the striking efficacy of imatinib for the treatment of myeloproliferative neoplasms with PDGFRB translocations/fusions (PMID: 12181402, 16960151, 18950453, 22897847, 14504092, 26355392), the largest of which (n=26) showed an overall response rate of 96% and ten-year overall survival of 90% in such patients (PMID: 24687085). In total, case studies have indicated that about 45% of patients have complete responses to imatinib and 39% have major responses (PMID: 1516603, 12676775). In a long-term study of twelve patients with chronic myeloproliferative disorders harboring PDGFRB fusions who were treated with imatinib, all patients showed a rapid response to treatment as measured by complete molecular and cytogenetic remission, and the median duration of cytogenetic responses was 47 months with only two patients progressing to relapse and death (PMID: 16960151)."
['Fusions'],"[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]",['Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.'],LEVEL_1,LEVEL_Fda2,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}",[],"['16960151', '12676775', '12181402', '14504092', '18950453', '24687085', '22897847', '26355392', '1516603']",[],"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Numerous small clinical trials and case reports have demonstrated the striking efficacy of imatinib for the treatment of myeloproliferative neoplasms with PDGFRB translocations/fusions (PMID: 12181402, 16960151, 18950453, 22897847, 14504092, 26355392), the largest of which (n=26) showed an overall response rate of 96% and ten-year overall survival of 90% in such patients (PMID: 24687085). In total, case studies have indicated that about 45% of patients have complete responses to imatinib and 39% have major responses (PMID: 1516603, 12676775). In a long-term study of twelve patients with chronic myeloproliferative disorders harboring PDGFRB fusions who were treated with imatinib, all patients showed a rapid response to treatment as measured by complete molecular and cytogenetic remission, and the median duration of cytogenetic responses was 47 months with only two patients progressing to relapse and death (PMID: 16960151)."
['Fusions'],"[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]",['Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements.'],LEVEL_1,LEVEL_Fda2,"{'id': 285, 'code': 'MDS/MPN', 'color': 'LightSalmon', 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}",[],"['16960151', '12676775', '12181402', '14504092', '18950453', '24687085', '22897847', '26355392', '1516603']",[],"Imatinib, a small molecule inhibitor of KIT, PDGFRB and other kinases, is FDA-approved for adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements. Numerous small clinical trials and case reports have demonstrated the striking efficacy of imatinib for the treatment of myeloproliferative neoplasms with PDGFRB translocations/fusions (PMID: 12181402, 16960151, 18950453, 22897847, 14504092, 26355392), the largest of which (n=26) showed an overall response rate of 96% and ten-year overall survival of 90% in such patients (PMID: 24687085). In total, case studies have indicated that about 45% of patients have complete responses to imatinib and 39% have major responses (PMID: 1516603, 12676775). In a long-term study of twelve patients with chronic myeloproliferative disorders harboring PDGFRB fusions who were treated with imatinib, all patients showed a rapid response to treatment as measured by complete molecular and cytogenetic remission, and the median duration of cytogenetic responses was 47 months with only two patients progressing to relapse and death (PMID: 16960151)."
